Emerging in the field of obesity treatment, retatrutide presents a distinct approach. Beyond many available medications, retatrutide operates as a dual agonist, concurrently engaging both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. The concurrent engagement encourages several advantageous effects, such as